A phage-targeting strategy for the design of spatiotemporal drug delivery from grafted matrices

Ritsuko Sawada1,2, Carrie Y Peterson1, Ana Maria Gonzalez3, Bruce M Potenza1, Barbara Mueller4, Raul Coimbra1, Brian P Eliceiri1, Andrew Baird1,3*

Abstract

Background: The natural response to injury is dynamic and normally consists of complex temporal and spatial cellular changes in gene expression, which, when acting in synchrony, result in patent tissue repair and, in some instances, regeneration. However, current therapeutic regimens are static and most rely on matrices, gels and engineered skin tissue. Accordingly, there is a need to design next-generation grafting materials to enable biotherapeutic spatiotemporal targeting from clinically approved matrices. To this end, rather then focus on developing completely new grafting materials, we investigated whether phage display could be deployed onto clinically approved synthetic grafts to identify peptide motifs capable of linking pharmaceutical drugs with differential affinities and eventually, control drug delivery from matrices over both space and time.

Methods: To test this hypothesis, we biopanned combinatorial peptide libraries onto different formulations of a wound-healing matrix (Integra®) and eluted the bound peptides with 1) high salt, 2) collagen and glycosaminoglycan or 3) low pH. After three to six rounds of biopanning, phage recovery and phage amplification of the bound particles, any phage that had acquired a capacity to bind the matrix was sequenced.

Results: In this first report, we identify distinct classes of matrix-binding peptides which elute differently from the screened matrix and demonstrate that they can be applied in a spatially relevant manner.

Conclusions: We suggest that further applications of these combinatorial techniques to wound-healing matrices may offer a new way to improve the performance of clinically approved matrices so as to introduce temporal and spatial control over drug delivery.

Background

Synthetic grafts for full-thickness acute and chronic wounds have emerged as an important tool in the surgical management of cutaneous injuries [1-5]. Recognizing that significant improvements are still needed, several investigators have proposed that a combination of matrices with biotherapeutics would be an important direction in the development of next generation grafts [6-11]. Although it may be possible to create new matrices de novo, one promising approach has involved adding biotherapeutics and gene-based medicines to commonly used and clinically approved matrices before their deployment [1,2,6,7,10-16]. Although this approach builds on a significant amount of clinical experience, the results have unfortunately been variable, and furthermore, the approach is not amenable to treatment after graft placement. For example, gene-activated matrices (GAM) [17-21] require preformulation of genes within collagen matrices and, although we have used wound-healing matrices (Integra®; Integra LifeSciences, Plainsboro, NJ, USA) in animal models of wound healing to evaluate exogenous gene delivery at the site of injury after deployment [21,22], the response with different strategies has been variable, presumably because of changes in DNA/DNA vector-fixation capacity in already deployed matrices.

A crucial factor in the inclusion of candidate biotherapeutics into the wound bed is the assumption that factors, in particular growth factors, will have the necessary bioavailability to elicit a biologic response at the right place and at the right time [6,9,12]. Accordingly, the
disappointing performance of recombinant growth factors and gene medicines in various clinical paradigms [23-30] may simply reflect the pharmacokinetics of these factors in the wound bed, their stability in a protease-rich environment, and their spatial distribution on matrices. Although the use of synthetic and semisynthetic grafts may have achieved widespread clinical use, there remains an important challenge to transform these first-generation matrices into dynamic, spatiotemporally sensitive, next-generation drug-deployment vehicles.

One way to monitor the changes in spatiotemporal responsiveness to therapeutics has involved analyzing the wound-bed genome [31-34], transcriptome [35-38] and proteome [35,39] for clues as to what genes are active, and when and where. Another approach involves evaluating changes in endogenous gene expression non-invasively and in real time [40-42]. To this end, we have shown that it is possible to monitor non-invasively any changes in vascularization and permeability after grafting [22], and that both endogenous and exogenous gene expression can be monitored noninvasively after placement of tissue grafts [21]. Because the identification of when and where drug targets are expressed defines the parameters of spatiotemporal delivery, we sought to describe two endpoints, angiogenesis and inflammation, to guide our drug-delivery efforts.

In the present study, we tested whether combinatorial tools such as phage display [43] could be used to help design next-generation matrices capable of drug delivery. If so, we reasoned that a genetic selection of active peptides might help identify unique classes of peptides with different affinities and specificities, whose activities are dependent, a priori, on the specific protocol used for their selection. We first focused on characterizing the dynamic nature of the endogenous gene expression in the wound bed in an attempt to characterize aspects of the temporal and spatial kinetics of tissue responsiveness. We then focused on identifying specific peptide motifs that could be deployed to target the graft with specific, and presumably differential, affinities. In designing the targeting strategy for these proof-of-concept experiments, we selected a clinically approved graft that is 1) in wide use for both full-thickness burns and chronic wounds, 2) a biosynthetic formulation that is stable at room temperature, 3) suitable for combinatorial screening and 4) amenable to biopanning using phage display. We show how an Integra®-based matrix that is a composite of modified type I bovine collagen and chondroitin sulfate glycosaminoglycan (CS-GAG), can be used to select for peptide targeting. Moreover, having previously used this matrix to define the kinetics of vascular permeability and neovascularization in a full-thickness wound, we show that there are temporal and spatial changes in gene expression that accompany tissue repair, which specifically need targeting at different times and different locations. These data provide the first systematic evaluation of phage display to identify peptide motifs for biotherapeutic targeting to the wound bed. We also describe the screening protocols used to detect, identify and validate these peptides. The possibility that these findings could serve as a foundation to evolve static synthetic matrices into dynamic grafts that provide temporal and spatial control over drug delivery is discussed.

Results
We evaluated and subsequently deployed several strategies to identify peptides capable of interacting with the Integra® matrices. These included the use of 1) two different peptide libraries as starting materials including the PHD-C7C and PHD12 libraries; 2) different formulations of the target including intact, solubilized or cryostat-sectioned matrices for biopanning; 3) different elution buffers including chondroitin sulfate, low pH and high salt; and lastly 4) different blocking buffers including bovine serum albumin (BSA), phosphate-buffered saline containing 0.1% Tween (PBS-T), and non-fat milk (NFM) to limit non-specific binding of phage. These variations would allow us to select particles that display different classes of peptides with different affinities for the target matrix. The approaches used are detailed in Table 1 and summarized schematically in Figure 1.

Temporal and spatial assessment of vascular remodeling and inflammation in vascular endothelial growth factor receptor-luciferase and Smad 2/3 binding element-luciferae transgenic mice
To assess spatiotemporal control of angiogenesis, we examined the activation of the vascular endothelial growth factor receptor (VEGFR)2 gene (vegfr2) in a transgenic mouse that expresses firefly luciferase under the regulation of the VEGFR2 promoter. Whereas Zhang et al. [44] used this model to assess contact sensitivity, we sought to define the kinetics of VEGF-dependent responsiveness in a full-thickness wound grafted with Integra® to determine its correlation with the vascular remodeling seen in our injury model [21,22]. Representative images of grafted wounds in each of these mice localized VEGFR2-con- trolled luciferase gene expression to the rim of the wound, with a peak of gene expression at 7 days (Figure 2A). As expected from our previous immunohistochemical studies [21,22], the localization of the vegfr2 gene expression in the angiogenic rim corresponded to the region of most active angiogenesis in these grafts. Over the 14-day period in which these full-thickness wounds consolidated, contracted and healed, peak VEGFR2 promoter activation was recorded on day 7 (Figure 2A). These observations suggest that the VEGFR2 promoter activation of luciferase in intact transgenic mice can be used as a model to both
localize the distribution of vascular remodeling events and quantify the kinetics of expression.

Signaling through the transforming growth factor (TFF)-β and Smad 2/3 pathway, in contrast, has been associated in various in vitro and in vivo models with inflammation and scarring [45,46]. The binding element for the Smad 2 and 3 transcription factors can be used to monitor smad2/3 gene activation. Therefore, to determine the kinetics of activation of this pathway, we examined the activation of this Smad Binding Element (SBE) promoter in a luciferase transgenic mouse after a full-thickness wound and graft. Results showed luciferase activity at 3 days distributed across the wound bed, which resolved by day 7 (Figure 2B). Quantification of the luciferase activity showed a peak as early as post-operative day 3 (the earliest day examined), which declined through the 14-day time course. Whereas TGF-β-Smad2/3 pathway signaling is generally associated with scar formation, the determinants for which are thought to be a late response of the wound bed, these data suggest that SBE signaling may be an early response.

Screening strategy for identification of matrix targeting peptides

In light of the spatial and temporal changes seen in the expression of endogenous genes after injury, we sought to design a drug-immobilization strategy that would enable biotherapeutic absorption at specific sites within target matrices. It is our long-term goal to modulate biotherapeutic affinities to matrices so as to introduce intrinsic temporal and spatial control of biotherapeutic release. With this end in mind, we designed and deployed a multifaceted phage display screening strategy to identify peptide motifs capable of differential binding to Integra® matrices. By comparing the results obtained from PHD-C7C and PHD12 phage libraries, we hoped to generate different classes of linker candidates for biotherapeutic delivery. By evaluating specific blocking and elution strategies, we reasoned that we could preferentially select peptides with differential affinities and hence increase the heterogeneity of the genetic selection of IT targeting peptide candidates. This overall strategy is described in Figure 1 and summarized in Table 1, and the identity of peptides recovered is presented in Table 2 and Table 3.

Identification of matrix binding peptides eluted under different conditions

The first series of experiments involved screening the PHD-C7C library on intact Integra® bilayer matrix
Table 2 Identification of Integra® (IT) matrix targeting peptides from libraries eluted by acid, acid salt and chondroitin sulfate

| Peptide Code | IT1b | IT6c | IT6 | IT6 R (GAGd) | IT7c | IT7 | IT7 R3 (GAG) |
|--------------|------|------|-----|-------------|------|-----|--------------|
| BSA          | ITI  | BSA  | IT6-BA (Figure 4A) | BSA | IT6-CG (Figure 4B) | BSA | IT7-BA (Figure 5A) | BSA | IT7-CG (Figure 5B) |
| 3            | CTS  | A-1  | CNPLHRQHC | CG-1 | CLSTSSKSC | BA-1 | HWHDWMSWRRD | CG-1 | AYYPQNH-KSNAE |
| 3.2          | CTP  | A-2  | CFKHSWQC | CG-2 | CLSTSSKSC | BA-2 | SMWPWYSQWAR | CG-2 | APQYQHNOATHT |
| 3.7          | CNM  | A-3  | CPTPLSLC | CG-3 | CLSTSSKSC | BA-3 | TLGDRTYRKPI | CG-3 | SITWTHPGALQ |
| 3.8          | CPN  | A-4  | CINASKPLC | CG-4 | CQTSANTQC | BA-4 | SFSTMNAPGGS | CG-4 | AGLHPRLSLESPL |
| 4            | CIN  | A-5  | CNRMVQPMC | CG-5 | CGVPAGSTC | BA-5 | WYMPWWSAGQAA | CG-5 | HPGNRSLDPLNH |
| 4.2          | CKS  | A-6  | CNLALTQAC | CG-6 | CLSTSSKSC | BA-7 | QKIRRPVHVR | CG-6 | LLADTTH-RPWT |
| 4.3          | CPQ  | A-7  | CFKSSQOC | CG-7 | CLSTSSKSC | BA-8 | GAFHKHARLJ | CG-7 | ATQKPTRLESHV |
| 4.5          | CPQ  | A-8  | CQPEPSNAC | CG-8 | CLATKHNC | BA-9 | WYMPWWSAGQAA | CG-8 | NPSNLQYRPA |
| 4.7          | CPQ  | A-9  | CPSHIVQC | CG-9 | CLSTSSKSC | BA-10 | WNRSPLPYGCA | CG-9 | SKAHDISQROPP |
| 4.8          | CSN  | A-10 | CNPLHRQHC | CG-10 | CDGVSTKHC | BA-11 | SLWQRFWPLD | CG-10 | VNRPGENLSSP |
| 4.9          | CNP  | A-11 | CSKTFVRRC | CG-11 | CLSTSSKSC | BA-12 | HWHDWMSWRRD | CG-11 | AYYPQNH-KSNAE |
| 4.10         | CNG  | A-12 | CFKHSQOC | CG-12 | CLSTSSKSC | BA-13 | DLALNTPPSPD | CG-12 | SNOAPALFQOL |
| 4.13         | CTP  | A-13 | CFKHSQOC | CG-13 | CLSTSSKSC | BA-14 | SHALPWTSSA | CG-13 | YSPASKPSVPSL |
| 4.15         | CEG  | A-14 | CFKHSQOC | CG-14 | CLSTSSKSC | BA-15 | WHYNSWYRVPVM | CG-14 | SVSVGKMPSRPP |
| 4.18         | CNQ  | A-15 | CFKHSQOC | CG-15 | CMPSPSLK | - - | - - | - - | - - |
| 4.20         | CTP  | A-16 | CFKHSQOC | CG-16 | - - | - - | - - | - - | - - |
| 4.22         | CNQ  | A-17 | CFKHSQOC | CG-17 | - - | - - | - - | - - | - - |
| 4.23         | CNQ  | A-18 | CFKHSQOC | CG-18 | - - | - - | - - | - - | - - |
| 4.24         | CNQ  | A-19 | CFKHSQOC | CG-19 | - - | - - | - - | - - | - - |
| 4.25         | CNQ  | A-20 | CFKHSQOC | CG-20 | - - | - - | - - | - - | - - |

aThe sequences of peptides isolated using the biopanning strategies IT1, IT6 and IT7 are presented along with their code numbers for reference.

bIT1 was screened against intact matrix and only acid eluates were evaluated.

cIT6 and IT7 used both acid and GAG elutions.

dGAG = glycosaminoglycan.

BSA = bovine serum albumin.
| IT8<sup>a</sup> | R3 (pH 2) | IT8 | R3 (NaCl) | IT8 | R3 (pH 2) | IT8 | R3 (NaCl) | IT8 | R4 (pH 2) | IT8 | R4 (pH 2) | IT9<sup>b</sup> | R4 (pH 2) |
|-----------------|----------|-----|----------|-----|----------|-----|----------|-----|----------|-----|----------|-----|----------|
| BSA             | IT8-BA   | BSA | IT8-BA   | PO4 | IT8-PA   | PO4 | IT8-PAS- | BSA | IT8-BA   | PO4 | IT8-PAS-  | NFM | IT9-MA   |
| Figure 6A       | Figure 6B|     | Figure 6C|     | Figure 6D|     | Figure 7 |     |          |     |          |     |          |
| BA1             | CVPPSARIC| BAS1| CHMSPRHC | PA1 | CVPSSARIC| PA4 | CHTAQPRAC| R4BA1| CKGPSRHIC| R4PA1| CKHDDTYC | MA1 | HETFPSPRANSV |
| BA2             | CRMHDSKAC| BAS2| CTPHKQWSC| PA2 | CRMHDSKAC| PA5 | CHTAQPRAC| R4BA2| CKGPSRHIC| R4PA2| CKHDDTYC | MA2 | HETFPSPRANSV |
| BA3             | CRMHDSKAC| BAS3| CKQQLMTNC| PA3 | CRMHDSKAC| PA6 | CHTAQPRAC| R4BA3| CSMTKTHC | R4PA3| CSMTKTHC | MA3 | HETFPSPRANSV |
| BA4             | CRMHDSKAC| BAS4| CTVPTPLHC| PA4 | CRMHDSKAC| PA8 | CHTAQPRAC| R4BA4| CDNKRSPAC| R4PA4| CDNKRSPAC| MA4 | HETFPSPRANSV |
| BA5             | CRMHDSKAC| BAS5| CDSNTHLQC| PA5 | CRMHDSKAC| PA9 | CHTAQPRAC| R4BA5| CHYTPSKAC| R4PA5| CHYTPSKAC| MA5 | SQYIATGPRQIA |
| BA6             | CRMHDSKAC| BAS6| CTSNQKQC | PA6 | CRMHDSKAC| PA10| CHTAQPRAC| R4BA7| CQFSKSCQSC| R4PA6| CQFSKSCQSC| MA6 | WDTEKASPLSPL |
| BA7             | CRMHDSKAC| BAS7| CHLHMKRKC| PA7 | CRMHDSKAC| PA11| CHTAQPRAC| R4BA8| CTDNTRRDC| R4PA8| CTDNTRRDC| MA7 | HETFPSPRANSV |
| BA8             | CRMHDSKAC| BAS8| CMTKPRMSC| PA8 | CRMHDSKAC| PA12| CHTAQPRAC| R4BA10| CPRFSSSPSC| R4AP9| CHATPYPKHC| MB8 | HETFPSPRANSV |
| BA10            | CRMHDSKAC| BAS10| CYKHNQORC| PA9 | CRMHDSKAC| PA13| CHTAQPRAC| R4BA11| CPMNHQSC| R4PA10| CPMNHQSC| MA10| DHTGKSPQLFHN |
| BA11            | CRMHDSKAC| BAS11| CHLSPPKSC| PA10| CRMHDSKAC| PA14| CHTAQPRAC| R4BA12| CSATQSMC| R4PA11| CSATQSMC| MA11| CSATQSMC |
| BA12            | CRMHDSKAC| BAS12| CTTSKPRDC| PA11| CRMHDSKAC| PA15| CHTAQPRAC| R4BA13| CPLKGLATC| R4PA12| CPLKGLATC| MA12| CPLKGLATC |
| BA13            | CRMHDSKAC| BAS13| CTAGLTSNC| PA12| CRMHDSKAC| PA16| CHTAQPRAC| R4BA14| CTGKPTLKC| R4PA13| CTGKPTLKC| MA13| CTGKPTLKC |
| BA14            | CRMHDSKAC| BAS14| CPSSMPSRC| PA13| CRMHDSKAC| PA17| CHTAQPRAC| R4PA14| CGMNAFRAC| MA14| CGMNAFRAC| MA14| CGMNAFRAC |
| BA15            | CRMHDSKAC| BAS15| CTPSHTDC| PA15| CRMHDSKAC| PA18| CHTAQPRAC| R4PA16| CTYKSTTC| MA16| CTYKSTTC | MA16| CTYKSTTC |
| -               | -        | -   | -        | -   | -        | -   | -        | -   | -        | -   | -        | -   | -        |
| -               | -        | -   | -        | -   | -        | -   | -        | -   | -        | -   | -        | -   | -        |
| -               | -        | -   | -        | -   | -        | -   | -        | -   | -        | -   | -        | -   | -        |

<sup>a</sup>The sequences of peptides pulled from the biopanning strategies IT8 and IT9 are presented along with their code numbers for reference.

<sup>b</sup>IT8 was screened against matrix sonicated samples blocked with BSA or PBS-T, and the peptide sequences were generated from both acid and GAG elutions.

<sup>c</sup>IT9 was biopanned from thin sections of matrix blocked with NFM or PBS-T, and only the acid/high salt eluates evaluated.
wound dressings. As expected, the recovery of binding particles during the four rounds of biopanning initially decreased, but then subsequently increased 40-fold. We identified two distinct motifs of peptides with this selection strategy: XAXSX and XTHPX (Table 2). The former (XXAXSXX) was detected in sequences recovered from the third round of screening, and the latter (XXTHPXX) was detected in the fourth round.

We performed a phylogenetic analysis of these Integra®-targeting (IT) peptides, which identified one major subfamily represented by peptides IT1-4.8 with two distal sequences (IT1, peptide 4.5 and IT1, peptide 4.20) (Figure 3). Further selection in a fifth round failed to enrich and found increased non-specific adsorption to BSA blocking agents and further screening was discontinued (data not shown).

In IT6 and IT7 screens (Table 2), phages were eluted with either low pH or by displacement with exogenous chondroitin sulfate to obtain particles with different binding capacities. The target for the biopanning was a homogenized and sonicated Integra® matrix that was absorbed to ELISA plates (see Methods). This approach was designed to minimize non-specific sequestration of particles in the highly fenestrated matrix during the biopanning procedure. In one biopanning strategy (IT6), we evaluated peptides recovered from a screen of the PHD-C7C library described above. In a second biopanning set, we analyzed the PHD12 library of linear peptides 12 amino acids long (IT7). In both instances, we were able to recover peptides with distinct motifs, which upon analyses collapsed into separate families (Figure 4A). For example, sequence collapse within the IT6 acid eluate identified one main family of related peptides represented by the sequence of IT6-A2 and a putative consensus sequence of XKHSXH, whereas there were two outlying peptides represented by IT6-A5 and IT6-A11. Peptides eluted with acid/high salt fell into the prime family of the ITA2 peptides recovered, suggesting that the salt wash did not provide any selective advantage. Mining the PHD12 library under these same conditions showed more heterogeneity (Figure 4B) but the sequences nevertheless collapsed to a prime sequence of WMWS represented by the IT7-A1.

The collapse of selected peptides from the library is perhaps best illustrated by the sequences obtained from the chondroitin sulfate elutions in IT6. Of 15 sequences, nine were identical and closely related (0.429) to others (IT6-CG8) (Table 2; Figure 5A). The formatted alignments show the importance of Ser/Thr in the selection of these peptides. This was less obvious in the collapse of the PHD12 library in the third round of selection by chondroitin sulfate elution (Figure 5B). Whereas there was one main family of related peptides represented by IT7-3CG, the motif seemed to revolve around the positive charge of histidine (XTHHX) rather then the presence of a hydroxyl group of serine or threonine, yet there are similar alignments in XXLESXX, such as IT7-CG6.
Figure 4 Phylogenic tree of peptide targeting candidates using acid elution of partially solubilized matrix sonicated samples. Peptide sequences were obtained after the third round of screening using (A) the IT6 protocol, which biopanned using the PHD-C7C library or (B) the IT7 protocol, which used the PHD12 library as starting material. In both instances, the phage were recovered from the acid eluates of washed sonicated samples. Sequences were analyzed for structural relatedness using MacVector sequence analysis software. Library collapse was reflected by an increased recovery of 300-fold in IT7 over the three rounds of biopanning.
Figure 5 Phylogenic tree of peptide targeting candidates using chondroitin sulfate elution from matrix sonicated samples. Peptide sequences were obtained after the third round of screening using (A) the IT6 protocol, which biopanned using the C7C library or (B) the IT7 protocol, which used the PHD12 library as starting material. In both instances the phage were recovered from the chondroitin sulfate (CS)-glycosaminoglycan (GAG) eluates of washed sonicated matrix samples, which contained CG to remove bound peptides. Sequences were analyzed for structural relatedness using MacVector sequence analysis software. Library collapse was indicated by an increased recovery of 400-fold in IT7 over the three rounds of biopanning.
Identification of matrix-targeting peptides under different blocking conditions

There was concern that if the IT6 and IT7 protocols above were adapted to evaluate the yields from PHD-C7C and PHD12 libraries, respectively, on sonicated matrix homogenates, selection bias in the combinatorial screens could be generated by the blocking buffer and not just by virtue of sequestration within the matrix, as suspected with IT1 peptides. To address this possibility, we evaluated the identity of binding peptides selected onto thin (10 μm) sections of matrix. Reasoning that thin sections would minimize sequestration within the matrix fenestrations, crysostat processed matrices were used for biopanning. The results from the four approaches are presented in Table 3. Both the acid and acid/salt eluates of PHD-C7C biopanning in the presence of bovine serum albumin (BSA) identified 14 peptides, which by phylogenic analyses were related, except for two sequences (Figure 6A). Within this family of sequences there were two subfamilies with the consensus sequences XSTSXQX and SXSXH, represented by peptides IT8-3A4 and IT8-3A2, respectively. There was less homology when the biopanning was performed in the absence of BSA (Table 3) and there were three families identified, of which one further segregated into acid and acid/salt motifs (Figure 6B). With a fourth round of screening, the peptides eluting with acid from BSA-blocked sections (Table 3) collapsed further to reveal the XXSXSSX motif found in peptide IT84A10, whereas the non-blocking fourth-round sequences collapsed towards a similar SSXXXTY sequence illustrated by IT8-4B3 (Figure 6C).

To further address possible biopanning bias that might be introduced by BSA blocking, we compared the screening selection with and without NFM when biopanning against the PHD12 library. After three rounds of processing in IT9, libraries collapsed to the extent that seven of 10 of sequences corresponded to one peptide (HETFPSPRANSV) in the NFM-blocked samples, which also had the XXSSSSX consensus (Figure 7A,B). All 20 sequences obtained from the non-blocked screen corresponded to a sequence not found in previous screens (AHKHKHPGHTA) (Table 3). Phylogenetic analyses of the peptides showed that the linkages between the peptides identified could be divided into three classes that, as in other cases, were represented by a central core group of related peptides and two distally related sequences. Their distal sequences corresponded to outliers of the NFM-blocking and non-blocking screens, respectively.

Evaluation of candidate peptides for binding capacity

The strategy to confer temporal and spatial control to drug release on the matrices involves the use of peptides with differential affinities to components of the deployed graft. To this end, we evaluated peptide binding to the matrix relative to controls by direct incubation onto the target. Representative results for different targeting
peptides are presented in Figure 8. The initial screen involved direct binding analyses of the targeted particles as illustrated for the IT8 peptides recovered in the presence or absence of blocking BSA (Figure 8A). Under the ELISA conditions used (see Methods), background binding was low and there was an approximately 10^5 increase in binding. Although all of the peptides selected as candidates showed specific binding, some (for example, IT8-R4PA21) seemed to have greater capacity. This affinity is evaluated in dose response curves which, showed a dose-dependent increase in binding that reflects the affinity the peptides confer to the particles (Figure 8B). In this specific example, binding of peptides selected by chondroitin sulfate displacement was evaluated in an ELISA using the glycosaminoglycan to capture targeted phage. Although there was a 10^5-fold increase in saturable binding, the affinities were narrow and detectable over a two- to three-fold change in concentrations. In-depth analysis of specificity, capacity, affinity and avidity of all the peptide candidates is underway on matrix, sonicated samples and GAG-coated plates to select targeting leads for evaluation in preclinical studies.

Validation of peptides on intact matrix

Although changes in affinity might meet the long-term goal to confer temporal control over delivery, we also wanted to establish whether the targeting peptides could be compatible with spatial control. To this end, we sought to decorate matrices so that they could be designed for drug delivery in a spatially relevant manner, for example in the angiogenic ring described in Figure 2A. Targeted phage can be placed onto sections so as to absorb to specific loci (Figure 8C). In the case of targeting VEGFR2, particles were placed in the periphery of the matrix. In one example (Figure 8C, number 2) the peptide IT6-A7, derived form the PHD-C7 library and with the sequence CFKHSSHQC displayed on the phage, was placed as parallel lines on sections, and the lines were clearly visualized by immunohistochemistry. In another example (Figure 8C, number 3), we demonstrated focal immobilization and hence, potential for targeting specific loci with the IT6-A7 particle, identified from the PHD12 library, with the targeting sequence SQIDYATGPRQA displayed on the phage. When placed as points on sections, the position (lower left corner) of the IT6-A7 particle was clearly visualized by immunohistochemistry. This spatial immobilization, coupled with the temporal differences in binding conferred by differential affinities, provides the first step towards the design of spatially and temporally controlled drug delivery from matrices.

Discussion

In this paper, we provide data supporting the use of phage display to identify targeting peptides for Integra®, a surgical dressing used for the treatment of full-thickness burns and wounds and approved by the US Food and Drug Administration. We evaluated several conditions for phage targeting of the grafting material including 1) different starting peptide libraries, 2) different elution strategies, 3) different blocking strategies and 3) different formulations of the matrix material to facilitate selection of peptides with different binding characteristics. Although our study focused on the use of Integra® as a matrix product, any matrix formulation could be subjected to similar evaluation and explored for possible targeting peptides. In fact, it is possible that alternative proteins to CS-GAG may have peptide sequences with widely different affinities. To this end, it is important to note that the peptides identified here represent first-generation sequences that can be optimized and converted to leads by further exploration of their affinities, specificities and relative elution characteristics.

We demonstrate an application of phage display towards mining the range of various binding sites presumably present in a collagen-glycosaminoglycan matrix such as Integra®. Further investigation is needed to determine whether these binding motifs can be used for the design of modified biotherapeutics to complement the biologic activity of cutaneous wound healing and tissue repair. Thus, although the biologic significance of these binding sites remains to be determined in vivo, the identification of these candidate motifs is a necessary first step towards the design of spatiotemporal matrix-deployed biotherapeutics.

Integra® is an engineered bilayer matrix that consists primarily of GAG with denatured bovine collagen. This
acellular synthetic dressing has clinical applications in full-thickness burn injury and wounds, and more limited uses in tissue regeneration. The capacity to combine the use of such a wound dressing with a molecular technique such as phage display presents the possibility of designing strategies that can exploit the different pharmacokinetic properties of the peptides identified. For example, we anticipate that a slow and stable release of growth factors, cytokines and other remodeling factors could be used to modulate the natural course of tissue repair. The matrix would act to stabilize the delivery of the pharmaceutical at the site of the wound bed in the precise location at which its activity can most influence wound healing (that is, angiogenic factors on the periphery and superficial surfaces of the matrix, and scar-limiting factors throughout). When key events in wound repair occur, such as granulation tissue growth and protease release into the matrix, local conditions would allow the release of the pharmaceutical drug into the wound to facilitate healing. Additionally, pharmaceuticals could be designed that would be released when exposed to wound exudates, leading to the protease-mediated degradation of substances that impede wound healing. Alternatively, the targeting peptides could be used to target nanoparticles, liposomes and viruses to matrices for gene delivery to the wound bed.

Phage display is a widely used combinatorial technique that has been used extensively since its discovery 25 years ago by Smith [47]. Numerous groups have used it to identify interacting peptides and their binding
partners in simple, complex and even in vivo environments [29,43,48-59], but to our knowledge, it has never been deployed for graft targeting per se, although a number of integrin targeting peptides have been identified and exploited [51,54,60,61]. Phage display has also been used to identify binding peptides for stem cells, immune cells, bacteria and recombinant proteins [43], and of particular interest to the studies described here, clotted plasma [57]. In this latter study, clotted plasma, an essential element of wound closure, was subjected to phage-library screening to identify peptide motifs that localized to the injured tissue and fibrin/fibronectin-containing tumors. Although our studies focused more on the experimental conditions for peptide identification than the specific binding motifs for a biosynthetic matrix, it is clear that the integrity of these motifs within a wound bed are changing and undergoing active remodeling, and may be altered. Accordingly, phage display may also be used to identify changes in binding sites as they change in the wound bed, by combining the approach described here with protocols involving in vivo biopanning paradigms, used by other laboratories [48,58,59]. This work is currently underway in our laboratories.

Although we began with the goal of using the discovered peptides for drug delivery to the wound bed from matrices, retargeted bacteriophages themselves may have intrinsic utility. There is a growing interest in the use of phage in the wound bed to control infection and biofilm development [62,63]. Indeed, Markoishvili et al [15] developed a novel sustained-release matrix using biodegradable polyester amides that are impregnated with bacteriophage and antibiotics to show efficacy in the management of infected venous stasis ulcers and other poorly healing wounds. Whether the peptides identified by phage display could enhance these sustained-release pharmacokinetics remains to be established. If so, they would require minimal reformulation. There are also significant advantages to the concept of using phage display peptides in the same structural context in which they were originally identified (that is, on the particle). It is for these very reasons that phage-based vectors for gene delivery have been put forth for development [64-66].

As emphasized by the changes we describe in the temporal and spatial distribution of VEGFR2 and SBE promoter activity after grafting (Figure 2), it is particularly apparent that one of the major hurdles faced by the field of tissue repair and regeneration is pharmacokinetic: different agents need to be delivered to different places at different times, depending on the state of repair [6,9,12]. This is a formidable challenge to regenerative sciences, because different agents also have different functions, depending on the context in which they are recognized by the cell. It is in view of this intrinsic complexity that deployment of a combinatorial method such as phage display to a combinatorial problem such as wound healing presents a novel approach to the clinical problem of tissue repair. It is interesting to speculate that emerging technologies such as in vivo biopanning may help exploit the intrinsic complexity of the wound-healing response for drug deployment. The studies presented here present a combinatorial approach towards targeting that uses traditional biopanning and peptide-selection techniques of phage display. Whether or not these techniques or other combinatorial methods (for example, using directed evolution) might enable the design and creation of the next-generation matrices remains to be determined. In the meantime, it will be important to evaluate the potential of matrix-targeting peptide candidates such as those described here for their utility in spatiotemporal drug delivery to the wound bed.

**Conclusions**

We demonstrate how phage-display technologies can be used to identify peptide sequences that interact with Integra® grafting matrices. We show that when multiple strategies are deployed in different classes of screening assays, they identify different classes of targeting peptides, which may each have differential value in the temporal-spatial targeting of drugs, biotherapeutics and nanoparticles to the wound bed.

**Methods**

**Characterization of gene expression after full-thickness injury**

**Mouse graft model**

All procedures were approved by the Institutional Animal Care and Use Committee at University of California, San Diego. Mice were anesthetized with isoflurane, then the dorsum of the animal was shaved to clear the field of fur and the surgical site prepared using aseptic techniques. A full-thickness circular wound measuring 15 mm in diameter was marked to the right of midline using a standard template, and the skin, subcutaneous tissue and fascia were excised. Integra® grafts of 15 mm in diameter were cut from aseptic sheets and secured in place with approximately seven 3-0 silk sutures. Immediately after surgery, animals received 1.4 ml normal saline resuscitation and 0.05 mg/kg buprenorphine subcutaneously. Animals were allowed to recover under observation, returned to the vivarium, checked daily and maintained in a 12-hour light/dark cycle with free access to food and water.

**Transgenic mouse models of gene expression**

Male transgenic mice expressing firefly luciferase under the regulation of SBE (Jackson Laboratories, Bar Harbor, ME, USA) and transgenic mice expressing firefly luciferase under the regulation of the VEGFR2 promoter (kind
gift of Dr. J. Molkentin; PMID 14656927) were used. The mice ranged in age from eight to 16 weeks old, and were handled as described previously [21].

**Non-invasive in vivo imaging of gene expression during wound healing**

Mice were anesthetized with isofluorane and given intraperitoneal injection with 1.5 mg of the substrate D-luciferin (Caliper Life Sciences, Hopkinton, MA, USA) in 150 μl saline. After a 5-minute incubation to obtain steady-state kinetics of substrate distribution, the still-anesthetized mice were imaged (Lumina CCD Imaging System’ Caliper Life Sciences) according to the manufacturer’s recommendations. Exposure-matched images were acquired (Living Image software, version 3.0; Caliper Life Sciences). All animal images shown in this study were exposure-matched (that is, matching color bar upper and lower limits in each panel). Regions of interest (ROI) showing bioluminescence were handled as described previously [21]. Images were collected on days 3, 7 and 14 after grafting.

**Phage display libraries**

As specifically indicated in Table 1, one of two commercial peptide libraries (New England Biolabs, Ipswich, MD, USA) were used. These libraries consisted of either 1) a disulfide-constrained heptapeptide (PHD-C7C) or 2) a dodecapeptide (PHD12) library. The randomized peptide segment of the PHD-C7C library is flanked by a pair of cysteine residues, which results in the display having peptide loops rather than linear sequences. All of the libraries have reported complexities in excess of 2 × 10^5 independent clones, and are displayed at the N-terminus of the minor coat protein pIII on M13 phage, at a valency of five peptides per virion. Unlike the PHD12 libraries, the first randomized position in the PHD-C7C library is preceded by Ala-Cys, and all of the libraries contain a short linker sequence (Gly-Gly-Gly-Ser) between the displayed peptide and pIII.

**Biopanning strategies for matrix binding peptide identification**

**Screening protocol 1: Intact matrix biopanning using different elution strategies**

The first protocols (IT1) (Table 1; Figure 1) involved screening the PHD-C7C library on intact Integra® bilayer matrix wound dressings (catalog number BMW4101, lot number 465012B; Integra®) that were first cut to fit into 24-well cell culture plates. Non-specific binding to these membranes was blocked by an overnight incubation with 5 mg/ml of BSA in PBS-T at 4°C. The following day, the blocking buffer was aspirated and washed in PBS-T. As indicated, the matrices were then incubated for 1 hour at room temperature with 2 × 10^12 wild type M13 phage [66,67] in 1% BSA to further block non-specific phage particle binding and enhance biopanning for displayed peptides. After washing these blocked matrices three times with PBS-T, 2 × 10^11 particles from the PHD-C7C library were added for 1 hour at room temperature in 1% BSA. Matrices were then processed with four washes of 1) PBS-T, 2) salt (0.5 mol/l NaCl) or 3) 0.2 mol/l glycine-PBS (pH 2.2) in 1% BSA. Particles remaining in the matrix were homogenized, and the recovered phage from each eluate was amplified, titered and further processed for the next round of screening. This process was repeated four times, after which the peptides were sequenced. Recoveries increased 40-fold over four rounds of biopanning.

**Screening protocol 2: dissociated matrix biopanning**

IT6 and IT7 were adapted from the protocol described above but used the PHD-C7C and PHD12 libraries, respectively, on sonicated matrix homogenates instead of intact matrix. This biopanning was specifically designed to address the high non-specific background seen with protocol 1, presumably a result of sequestration in the fenestrations of the intact matrix. First, 24-well plates were coated with 100 ul of dissociated Integra®, which was prepared by homogenizing a 30 × 40 mm matrix in 50 ml PBS at 4°C, and adding 100 μl of a 1:5 diluent to coat wells overnight at 4°C. The following day, the wells were washed with PBS-T and blocked by the addition of 0.1% BSA in PBS-T for 1 hour at room temperature. After washing four times with PBS-T, phage was added for 1 hour at room temperature. Unbound particles were removed with further washes, and binding assessed with and without 0.2 mol/l glycine (pH 2.2) acid wash to evaluate binding affinity. Phage that acquired binding capacity were collected at the first round using 1) chondroitin sulfate 100 μg/mL in PBS, 2) 0.2 mol/l glycine in 1% BSA or 3) 0.2 mol/l glycine/0.5 mol/l NaCl washes, or from the particles bound to matrix after all washes. Each collection was then cycled through three or four more rounds of selection using the appropriate elution strategy (Table 1), and peptide sequences obtained to monitor library collapse to binding sequences.

**Screening protocol 3: cryostat section biopanning**

The third protocol deployed (IT8) was developed to identify binding peptides capable of binding directly to matrices, avoiding bias for the selection of peptide sequestration while retaining *in situ* biopanning on matrix sections. To this end, matrices were frozen in optimal cutting temperature (OCT) compound, and 10 μm sections were prepared using a cryostat and then placed onto frozen slides. These sections were thawed, washed and incubated with the PHD-C7C library as described in protocol 1, and the bound phage eluted from sections with 1) chondroitin sulfate, 2) high salt
(0.5 mol/l NaCl) or (3) 0.2 mol/l glycine (pH 2.2) in 1% BSA. The particles obtained in rounds 3 and 4 were used for sequencing.

Protocol 4: biopanning with and without NFM blocking
To address the possibility that selection bias was introduced by the nature of the blocking buffer, NFM was evaluated as a blocking agent in the IT9 screen to minimize non-specific binding. The profile of the targeting peptide candidates recovered was then compared with the use of PBS-T blocking buffer alone. In these experiments, the sonicated samples were processed into assay plates as above, but were either blocked during the pre-incubation with 1% non-fat milk in PBS-T, or with PBS-T alone. After 1 hour incubation with the PHD-C7c libraries, unbound peptides were removed with four PBS-T washes and bound phage were eluted with either 0.2 mol/l glycine (pH 2.2) in 1% BSA or 0.2 mol/l glycine/0.5 mol/l NaCl to distinguish different classes of binding peptides that would have different affinities and different kinetics of release from intact grafts.

DNA sequencing, peptide sequence deduction, homology and phylogeny analyses
DNA sequencing to deduce the peptide inserts encoded between the Kpn1/Acc65 1 and Eag 1 restriction sites was performed as described by the manufacturer (New England Biolabs, Ipswich, MA, USA). Single-strand phage was prepared with a commercial kit (Spin M13 Kit; Qiagen, Hilden, Germany). Single-strand phage was prepared with a commercial kit (Spin M13 Kit; Qiagen, Hilden, Germany). DNA sequencing was performed using primers supplied by the manufacturer. Single-strand phage was prepared with a commercial kit (Spin M13 Kit; Qiagen, Hilden, Germany). DNA sequencing was performed using primers supplied by the manufacturer. After quantification of yields on agarose gels, DNA sequencing was performed using primers supplied by the manufacturer. (CAACAAATCGTTTTAG GGTATGT) and (GCAAATGGAGTTGATCCCG). Data was analyzed using MacVector (Eastman Chemical Co., New Haven, CT, USA) and Vector NTI sequence analysis programs (Invitrogen, Carlsbad, CA, USA).

ELISA and IT peptide validation
To characterize the binding specificity of candidate IT peptides, we developed modified ELISAs using both 96-well and 24-well microtiter plate formats. Plates were coated with 100 μl of dissociated Integra® (prepared by homogenizing a 30 × 40 mm matrix in 50 ml PBS at 4°C and adding 100 μl of PBS-T diluent (1:5)) to coat wells overnight at 4°C. The following day, the wells were washed with PBS-T, and non-specific binding blocked by the addition of 0.1% BSA, non-fat milk or no protein in PBS-T for 1 hour at room temperature. After washing the wells four times with PBS-T, candidate phage were added for 1 hour at room temperature. Unbound particles were removed with further washes with PBS-T. Bound phage were detected by incubation for 2 hours with a horseradish peroxidase (HRP)-conjugated anti-M13 antibody (1:5000; MoBiTek, Gottingen, Germany), four washes with PBS-T and development of the HRP signal with chemiluminescence (Chemiglo; Alpha Innotech, San Leandro CA, USA).

To demonstrate spatially controlled binding of targeted particles, matrices were evaluated by imaging sections prepared in OCT. Negative controls (PBS) or targeted particles were deposited onto matrices in 5 μl PBS (1013 particles/ml) as either a dot or a continuous line, and allowed to bind for 90 minutes at room temperature. After rinsing and blocking with 0.1% milk in PBS-T for 1 hour, the sections were incubated with anti-M13 HRP-conjugated antibody (1:5000) for 1 hour at room temperature. Signal was detected using chemiluminescence and visualized (IVIS Lumina Xenogen Imaging system; Caliper Biosciences).

Statistical analysis
The change of bioluminescence after luciferin injection in wounds was analyzed in at least four animals in each group at each time point to obtain statistical significance. Student’s t-test was used to analyze the data, and P < 0.05 was considered significant.

Acknowledgements
We are grateful to Emelie Amburn, Alexandra Borboa, Jasmine Chukwueke, Niti Randhawa and Shuman Sun for excellent technical assistance. We thank Mr John Fitzgerald for preparation of the figures and Drs Michael Pierschbacher (San Diego, Ca) and Marc Gottlieb (Phoenix, Az) for their insight and helpful suggestions. This research was supported by the National Institutes of Health grants P20-GM078421 (AB), EY018479 (AB) and HL73936 (BE) and the CDMRP BC073891 (AB).

Author details
1Department of Surgery, Division of Trauma, Surgical Critical Care and Burns, University of California San Diego School of Medicine, 200 W. Arbor Dr., San Diego, CA 92103-8236 USA. 2Mabvax Therapeutics, Inc., 11588 Sorrento Valley Rd, Suite 20, San Diego, CA 92121 USA. 3College of Medicine and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK. 4Torey Pines Institute for Molecular Studies, 3550 General Atomics Court, San Diego, CA 92121-1122 USA.

Acknowledgements
We are grateful to Emelie Amburn, Alexandra Borboa, Jasmine Chukwueke, Niti Randhawa and Shuman Sun for excellent technical assistance. We thank Mr John Fitzgerald for preparation of the figures and Drs Michael Pierschbacher (San Diego, Ca) and Marc Gottlieb (Phoenix, Az) for their insight and helpful suggestions. This research was supported by the National Institutes of Health grants P20-GM078421 (AB), EY018479 (AB) and HL73936 (BE) and the CDMRP BC073891 (AB).

Author details
1Department of Surgery, Division of Trauma, Surgical Critical Care and Burns, University of California San Diego School of Medicine, 200 W. Arbor Dr., San Diego, CA 92103-8236 USA. 2Mabvax Therapeutics, Inc., 11588 Sorrento Valley Rd, Suite 20, San Diego, CA 92121 USA. 3College of Medicine and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK. 4Torey Pines Institute for Molecular Studies, 3550 General Atomics Court, San Diego, CA 92121-1122 USA.

Authors’ contributions
RS performed the phage biopanning, screening and sequencing experiments, and contributed to the manuscript. CYP performed the validation experiments and contributed to the manuscript. AMG assisted in design selection, protocols for analyses and interpretation of data. BMM contributed to the conception, design and coordination of the study. BP coordinated sample acquisition and assisted with experimental design. RC contributed to the coordination and design of the study, and the editing of the manuscript. BE contributed to the conception, design and coordination of the study, and performed the in vivo experiments. AB conceived of the study, and contributed to the conception, design and coordination of the work, and the writing and revising of the manuscript. All authors read and approved the final manuscript.

Declaration of competing interests
The authors declare that they have no competing interests.

Received: 17 June 2010 Accepted: 17 February 2011
Published: 17 February 2011

References
1. Chan ES, Lam PK, Liew CT, Lau HC, Yen RS, King WW: A new technique to resurface wounds with composite biocompatible epithelial graft and artificial skin. J Trauma 2001, 50:358-362.
2. Clayman MA, Clayman SM, Mozingo DW: The use of collagen- 
glycosaminoglycan copolymer (Integra™) for the repair of hypertrophic 
scars and keloids. J Burn Care Res 2006, 27:404-409.

3. Gravvanis AI, Tatsou DA, Iononou T, Gremouts G: The use of integra™ 
artificial dermis to minimize donor-site morbidity after suprascapular 
dissection of the radial forearm flap. Microsurgery 2007, 27:583-587.

4. Mis B, Rolland E, Ronfard V: Combined use of a collagen-based dermal 
substitute and a fibrin-based cultured epithelium: a step toward a total 
skin replacement for acute wounds. Burns 2004, 30:713-719.

5. Schneider J, Biedermann T, Widmer D, Montano I, Meuli M, Rechmann E, 
Schiesta C, Mattiresen versus Integra™: a comparative experimental study. 
Burns 2009, 35:511-517.

6. Chen RR, Silva EA, Yuan WW, Brock AA, Fischbach C, Lin AS, Guldberg RE, 
Mooney DJ: Integrated approach to designing growth factor delivery 
systems. FASEB J 2007, 21:3896-3903.

7. Hall H: Modified fibrin hydrogel matrices: both, 3D-scaffolds and local 
and controlled release systems to stimulate angiogenesis. Curr Pharm 
Des 2007, 13:3597-3607.

8. Huang S, Fu X: Naturally derived materials-based cell and drug delivery 
systems in skin regeneration. J Control Release 2009.

9. Silva EA, Mooney DJ: Spatiotemporal control of vascular endothelial 
growth factor delivery from injectable hydrogels enhances angiogenesis. 
Thromb Haemost 2007, 5:590-598.

10. Wilcke I, Lohmeyer JA, Liu S, Condurache A, Kruger S, Mailander P, 
Machens HG: VEGF(165) and bFGF protein-based therapy in a slow 
release system to improve angiogenesis in a bioartificial dermal 
substitute in vitro and in vivo. Langenbecks Arch Surg 2007, 
392:305-314.

11. Zech AH, Zeisberger SM, Ehrbar M, Djonov V, Weber CC, Ziemiecki A, 
Pascale EB, Hubbell JA: Engineered fibrin matrices for functional display of 
membrane bound growth factor-like activities: study of angiogenic signaling 
byparkin-B2. Biomaterials 2004, 25:3245-3257.

12. Cao L, Mooney DJ: Spatiotemporal control over growth factor signaling 
for therapeutic neovascularization. Adv Drug Deliv Rev 2007, 
59:1450-1455.

13. Håkkinen S, Parnell A, Rizzo S, Hall H, Hubbell JA: Biologically 
engineered protein-graft-poly(ethylene glycol) hydrogels: a cell adhesive 
and plasmin-degradable biosynthetic material for tissue repair. 
Biomacromolecules 2002, 3:710-713.

14. Marino P, Norreel JC, Mooney DJ: A polysialic acid mimetic peptide 
promotes functional recovery in a mouse model of spinal cord injury. Exp 
Neurol 2009, 216:133-147.

15. Markoukli T, Tsilkanidi G, Katsarava R, Morris JG Jr, Nizanowski R, 
Sawatsky A: Effects of simvastatin on angiogenic growth factors released 
at the site of microvascular injury. Thromb Haemost 2006, 95:1045-1047.

16. Smith TJ, Khatchatourians J, Lyman GH, Ozer H, Armitage JO, Balducci L, 
Bennett CL, Cantor SR, Crawford J, Cross SJ et al: 2006 update of 
recommendations for the use of white blood cell growth factors: an 
evidence-based clinical practice guideline. J Clin Oncol 2006, 
24:3187-3205.

17. Beckler J, Beckbauer M, Domschke W, Herbst H, Pohle T: Fibrin glue, 
healing of gastric mucosal injury, and expression of growth factors: 
results from a human in vivo study. Gastrointest Endosc 2005, 
61:560-567.

18. Goldman R: Growth factors and chronic wound healing: past, present, 
and future. Adv Skin Wound Care 2004, 17:23-35.

19. Smith PD, Polo M, Soler PM, McClintock JS, Maggi SP, Ko F, Robson CM: 
Efficacy of growth factors in the accelerated closure of interstices in 
explanted meshed human skin grafts. J Burn Care Rehabil 2000, 
21:5-9.

20. Anitura E: Plasma rich in growth factors: preliminary results of use in 
the preparation of future sites for implants. Int J Maxillofac Implants 
1999, 14:593-595.

21. Cabb JP, Brownstein BH, Watson MA, Shannon WD, Lasram JM, Ou Y, 
Storno GD, Morrissey Jr, Buchman TG, Karl IE, Hochkiss RS: Injury in the 
era of genomics. Shock 2001, 15:165-170.

22. Shaterian A, Borboa A, Sawada R, Costantini T, Potenza B, Coimbra R, 
Baird A, Elciceri BP: Real-time analysis of the kinetics of angiogenesis and 
vascular permeability in an animal model of wound healing. Burns 2009, 
35:611-617.

23. Calcutt NA, Jolivalt CG, Femythough P: Growth factors as therapeutics for 
diabetic neuropathy. Curr Drug Targets 2008, 9:47-59.

24. Lindas A, Celinska-Lowenhoff M, Stepien E, Nizanowski R, Tracz W, 
Sawatsky A: Effects of simvastatin on angiogenic growth factors released 
at the site of microvascular injury. Thromb Haemost 2006, 95:1045-1047.

25. Smith TJ, Khatchatourians J, Lyman GH, Ozer H, Armitage JO, Balducci L, 
Bennett CL, Cantor SR, Crawford J, Cross SJ et al: 2006 update of 
recommendations for the use of white blood cell growth factors: an 
evidence-based clinical practice guideline. J Clin Oncol 2006, 
24:3187-3205.

26. Rediel K, Riedel F, Goessels UR, Holle G, Germann G, Sauerdiek M: Current 
status of genetic modulation of growth factors in wound repair. Int J 
Mol Med 2006, 17:183-193.
45. Nakao A, Mike S, Hatano M, Okumura K, Tokuhis T, Ra C, Iwamoto I: Blockade of transforming growth factor beta/Smad signaling in T cells by overexpression of Smad7: enhances antigen-induced airway inflammation and airway reactivity. J Exp Med 2000, 192:151-158.

46. Harada T, Yoshimura A: Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev 2002, 13:413-421.

47. Smith GP: Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985, 228:1315-1317.

48. Arap W, Kolkinin MC, Trepel M, Lahdenranta J, Cardo-Vila M, Giordano RJ, Mintz PJ, Astephot PJ, Yao VJ, Vidal CI, et al: Steps toward mapping the human vasculature by phage display. Nat Med 2002, 8:121-127.

49. Brack SS, Silacci M, Bircher M, Neri D: Tumor-targeting properties of novel antibodies specific to the large isoform of tenasin-C. Clin Cancer Res 2006, 12:3200-3208.

50. Koivunen E, Arap W, Rajotte D, Lahdenranta J, Pasqualini R: Identification of receptor ligands with phage display peptide libraries. J Nucl Med 1999, 40:885-888.

51. Koivunen E, Gay DA, Ruoslahti E: Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library. J Biol Chem 1993, 268:20205-20210.

52. Lee SM, Lee EJ, Hong HY, Kwon MK, Kwon TH, Choi HY, Park RW, Kwon TG, Yoo ES, Yoon GS, et al: Targeting bladder tumor cells in vivo and in the urine with a peptide identified by phage display. Mol Cancer Res 2007, 5:11-19.

53. Muller OJ, Kaul F, Weitzman MD, Pasqualini R, Arap W, Kleinschmidt JA, Trepel M: Random peptide libraries displayed on adenovirus-associated virus to select for targeted gene therapy vectors. Nat Biotechnol 2003, 21:1040-1046.

54. Pasqualini R, Koivunen E, Ruoslahti E: A peptide isolated from phage display libraries is a structural and functional mimic of an RGD-binding site on integrins. J Cell Biol 1995, 130:1189-1196.

55. Pasqualini R, Ruoslahti E: Organ targeting in vivo using phage display peptide libraries. Nature 1996, 380:364-366.

56. Petrenko VA, Smith GP, Mazooji MM, Quinn T: Alpha-helically constrained phage display library. Protein Eng 2002, 15:943-950.

57. Pilch J, Brown DM, Komatsu M, Jarvisen TA, Yang M, Peter D, Hoffman RW, Ruoslahti E: Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds. Proc Natl Acad Sci USA 2006, 103:2800-2804.

58. Rajotte D, Arap W, Hagedorn M, Koivunen E, Pasqualini R, Ruoslahti E: Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 1998, 102:430-437.

59. Trepel M, Arap W, Pasqualini R: In vivo phage display and vascular heterogeneity: implications for targeted medicine. Curr Opin Chem Biol 2002, 6:399-404.

60. Koivunen E, Wang B, Ruoslahti E: Isolation of a highly specific ligand for the alpha 5 beta 1 integrin from a phage display library. J Cell Biol 1994, 124:373-380.

61. Kraft S, Diefenbach B, Mehta R, Jonczyk A, Luckenbach GA, Goodman SL: Definition of an unexpected ligand recognition motif for alphav beta6 integrin. J Biol Chem 1999, 274:1979-1985.

62. Cillo M, Dabirowski M, Weber-Dabrowska B, Woyton A: Bacteriophage treatment of suppurative skin infections. Arch Immunol Ther Exp (Warsz) 1987, 35:175-183.

63. Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, Sulakvelidze A: Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care 2009, 18:237-238, 240-233.

64. Burg MA, Jensen-Pergakes K, Gonzalez AM, Raynev P, Baird A, Larocca D: Enhanced phagemid particle gene transfer in camptothecin-treated carcinoma cells. Cancer Res 2002, 62:977-981.

65. Larocca D, Jensen-Pergakes K, Burg MA, Baird A: Receptor-targeted gene delivery using multivalent phagemid particles. Mol Ther 2001, 3:476-484.

66. Larocca D, Kassner PD, Witte A, Ladner RC, Pierce GF, Baird A: Gene transfer to mammalian cells using genetically targeted filamentous bacteriophage. FASEB J 1999, 13:277-279.

67. Kassner PD, Burg MA, Baird A, Larocca D: Genetic selection of phage engineered for receptor-mediated gene transfer to mammalian cells. Biochem Biophys Res Commun 1999, 264:921-928.